Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Discovery Laboratories — Corporate Update (October 2013)

16 slides from Windtree Therapeutics's corporate update, Oct 17, 2013

  1. Slide 1: Investor Conference Call October 17, 2013

    * NASDAQ: DSCO Investor Conference Call October 17, 2013 Discovery Laboratories, Inc.

  2. Slide 2: Forward Looking Statement

    * Forward Looking Statement To the extent that statements in this presentation are not strictly historical, including statements about the Company’s business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Comp

  3. Slide 3: Discovery Labs (DSCO) Initial focus – Neonatology

    * Discovery Labs (DSCO) Initial focus – Neonatology: Transform the treatment of respiratory distress syndrome (RDS) A specialty biotechnology company focused on advancing a new standard of care for critical care patients with respiratory disease DSCO Technology: Potential to improve the treatment of

  4. Slide 4: Transformation begins with SURFAXIN

    * Transformation begins with SURFAXIN® The first FDA-approved synthetic, peptide-containing (KL4) surfactant for use in RDS Only alternative to animal-derived surfactants available in the U.S. First approved therapy in over 10 years for the prevention of RDS Direct clinical outcome comparisons to th

  5. Slide 5: AEROSURF

    AERCSURF AEROSURF®: Drug-device product designed to deliver aerosolized KL4 surfactant directly into the lungs via nCPAP Being developed with the potential to: = Reduce the need for intubation or mechanical ventilation for pulmonary surfactant delivery = Enable treatment of a significantly greater n

  6. Slide 6: Technology: The Catalyst for Transformation

    * Pulmonary surfactant is essential for normal breathing Surfactant deficiency and dysfunction is associated with many respiratory disorders Historically, therapeutic surfactant products sourced from animal lungs – use and innovation limited Technology: The Catalyst for Transformation Cochrane & Rev

  7. Slide 7: RDS: The Neonatologist's Dilemma – Intubate or not?

    * RDS: The Neonatologist’s Dilemma – Intubate or not? Option A: Surfactant replacement therapy Intubation and invasive mechanical ventilation (MV) required Neonatologists will only intubate in cases of severe RDS where the benefits of invasive surfactant administration clearly outweigh the associate

  8. Slide 8: RDS in the U.S. - Unmet medical need

    * 360,000 premature infants each year are at risk for RDS; 160,000 would likely benefit from early surfactant therapy to address surfactant deficiency or insufficiency Option A: 45,000 with severe RDS receive 1st line surfactant via intubation / MV Option B: More than 70% of surfactant deficient inf

  9. Slide 9: AEROSURF: Potential to Resolve Neonatologist's Dilemma

    * AEROSURF® : Potential to Resolve Neonatologist’s Dilemma 160,000 premature infants in the U.S. would likely benefit from early surfactant therapy to address surfactant deficiency or insufficiency Option A: 45,000 with severe RDS receive 1st line surfactant via intubation / MV Option B: More than 7

  10. Slide 10: AEROSURF proposed development program

    * AEROSURF® proposed development program Primary goal – Address an unmet medical need – deliver aerosolized surfactant to preterm infants receiving nCPAP Clinical Target – Treatment of RDS in preterm infants receiving nCPAP Primary Comparator – nCPAP alone Key secondary program objectives: Reduce nC

  11. Slide 11: Phase 2a Program

    * AEROSURF® - Phase 2 Program Primary objective: To evaluate the safety and tolerability of a single exposure to aerosolized KL4 surfactant Escalating dose study evaluating three doses of increasing amounts of aerosolized KL4 surfactant Comparator: nCPAP alone Patient population: preterm infants 26

  12. Slide 12: Phase 2b Program

    * AEROSURF® - Phase 2 Program Primary objective: Determination of dose and efficacy margin Determination of optimal dose for phase 3 study. Define expected efficacy margin Patient population: preterm infants 26 to 32 weeks GA on nCPAP (n ~ 150 patients TBD post-Ph2a) Multicenter clinical trial The s

  13. Slide 13: Business Considerations

    * AEROSURF® - Business Considerations Comparatively modest incremental investment to achieve important phase 2 milestones 2012 – Q3’2013: Approx. $7M invested to develop capillary aerosol generator (CAG) for clinical program, cGMP lyophilized KL4-surfactant dosage form, and preparation for phase 2 c

  14. Slide 14: Market Considerations

    * AEROSURF® - Market Considerations U.S. market potential for AEROSURF – $600M to $1.0B+ 3 International market is comparable4 Unmet medical need: Approx.160,000 infants would likely benefit from early surfactant therapy of which 115,000 infants receive only nCPAP as first line therapy A mechanicall

  15. Slide 15: DSCO: Transforming the treatment of RDS in neonatology

    * DSCO: Transforming the treatment of RDS in neonatology Potential Patients Pharmacoeconomic Profile SURFAXIN® First synthetic, peptide-containing surfactant in the U.S. Animal-Derived Surfactants Value Proposition

  16. Slide 16: Q&A

    Q&A

Discovery Laboratories — Corporate Update (October 2013) on 6ix